During a routine production run of a common pharmaceutical product, the quality control (QC) team noted an increase in variability in the final product assay results. The acceptable range for…
The initial signal that sparked concerns around process robustness was an unexpected increase in out-of-specification (OOS) results during in-process testing of an API (Active Pharmaceutical Ingredient) batch. Production-quality control (QC)…
Identifying symptoms of a lack of process robustness begins at the shop floor or laboratory level. Below are common indicators that might suggest robustness issues.Click to read the full article.
Enhancing Process Robustness Evidence for Successful Technology Transfer In the pharmaceutical manufacturing industry, inadequate process robustness can lead to significant issues during technology transfer, impacting product quality, timelines, and regulatory…
Identifying initial signals that suggest a potential breakdown in process robustness is a critical first step in troubleshooting. Common symptoms may include:Click to read the full article.
Identifying symptoms indicative of potential robustness issues is the first critical step. Observe the following signals:Click to read the full article.
Identifying symptoms indicative of process variability is the first step toward maintaining robustness. Symptoms can manifest in several ways, including:Click to read the full article.
Observing abnormal production metrics or quality control failures can serve as a symptom indicating challenges in process robustness after scale-up. Symptoms may include:Click to read the full article.
Identifying early warning signs is crucial for recognizing potential failures in process robustness during scale-up. Symptoms can manifest as variations in product attributes, unexpected bioburden levels post-cleaning, or inconsistencies in…
During routine Quality Control (QC) testing of a solid dosage form, manufacturing personnel noted a higher-than-expected variability in dissolution profiles across different strengths of the same product. Specifically, samples from…
In early August, Quality Control (QC) flagged several batches of a tablet product exhibiting unexpected instability in Dissolution Profile testing across different strengths, including 5 mg, 10 mg, and 20…